WEP CLINICAL PARTNERS WITH KINIKSA TO LAUNCH ARCALYST NAMED PATIENT PROGRAM
WEP Clinical LTD (WEP), a specialist services company that [...]
WEP CLINICAL EXECUTES MASTER SERVICES AGREEMENT WITH MEDLAB TO BRING NANABIS™ AND NANOCBD™ TO PATIENTS IN UK AND EUROPE VIA ETHICAL NAMED PATIENT PROGRAMMES
WEP Clinical Ltd (WEP), a specialist services company that [...]
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH HORIZON THERAPEUTICS PLC TO LAUNCH NAMED PATIENT USE PROGRAM FOR TEPEZZA® (TEPROTUMUMAB-TRBW)
WEP Clinical today announced a partnership with Horizon Therapeutics [...]
WEP CLINICAL EXPANDS AVAILABILITY OF XENLETA® (LEFAMULIN) NAMED PATIENT PROGRAM IN PARTNERSHIP WITH NABRIVA THERAPEUTICS
WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased [...]
WEP CLINICAL EXTENDS PARTNERSHIP WITH BTG SPECIALTY PHARMACEUTICALS BY GAINING WORLDWIDE (EX-US) DISTRIBUTION RIGHTS FOR DIGIFAB®
WEP Clinical (WEP) announced today that it has extended [...]
WEP CLINICAL PARTNERS WITH US BIOTECH COMPANY FOR THE NAMED PATIENT SUPPLY OF CANCER PRODUCT IN EX-US COUNTRIES
WEP Clinical (WEP) announced today that, as of July [...]
WEP CLINICAL PARTNERS WITH BTG SPECIALTY PHARMACEUTICALS FOR EUROPEAN SUPPLY OF VORAXAZE®
WEP Clinical (WEP) announced today that it has entered [...]
WEP CLINICAL PARTNERS WITH NABRIVA THERAPEUTICS FOR THE NAMED PATIENT SUPPLY OF XENLETA® (LEFAMULIN)
WEP Clinical (WEP), a specialist pharmaceutical services company, has [...]
WEP CLINICAL JOINS WITH WREN HEALTHCARE TO PROVIDE HOME HEALTHCARE SERVICES
WEP Group Holdings Limited (WEP), a specialist CRO focused [...]
WEP CLINICAL PARTNERS WITH MYLAN TO PROVIDE PRODUCT FOR HIGHLY DRUG-RESISTANT TUBERCULOSIS
WEP Clinical (WEP), the specialist pharmaceutical services company, has [...]